1. McMurray J.J., Stewart J. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83(5):596-602.
2. Paulus W.J., Tschöpe C., Sanderson J.E. et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28(20):2539-50.
3. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Даниелян М.О. Первые результаты национального эпидемиологического исследования – эпидемиологическое обследование больных ХСН в реальной клинической практике – (ЭПОХА-О-ХСН). Журнал Сердечная недостаточность 2003;4(3):116-21.
4. Терещенко С.Н., Джаиани Н.А., Жиров И.В., Ускач Т.М. Хроническая сердечная недостаточность. Вопросы диагностики и лечения. М.: Анахарсис; 2006.
5. Braunwald E. ACE inhibitors — a cornerstone of treatment of heart failure. New Engl J Med 1991;325(5):351-3.
6. Garg R., Yusuf S. Overview of randomized trials of ACE Inhibitors on mortality and morbidity in pts with heart failure. JAMA 1995;273(18): 1450- 6.
7. Hunt S.A., Baker D.W., Chin M.H. et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38(7):2101-13.
8. Pfeffer M.A. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective. Herz 1993; 18 Suppl 1:430-5.
9. SOLVD Investigators. Effect of enalapril on survival in patients with rediced left ventricular ejection fractions and congestive heart gfailure. N Engl J Med 1991;325(5):293-302.
10. Kober L., Torp-Pedersen C., et al. A clinical trial of the angiotensin-convertingenzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333(25):1670-6.
11. Никифоров В.С., Свистов А.С. Современные направления применения ингибиторов ангиотензин-превращающего фермента в клинической практике. ФАРМиндекс ПРАКТИК 2005;(7):21-31.
12. Cohn J.N., Johnson G., Ziesche S. et al. A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325(5):303–10.
13. Pfeffer M., Braunwald E., Moye L. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327(10): 669–77.
14. Sigurdsson A., Swedberg K. Neurohormonal activation and congestive heart failure: Today’s experience with ACE inhibitors and rationale for their use. Eur Heart J 1995;16 Suppl N:65-72.
15. DiBianco R. ACE inhibitirs in the treatment of heart failure. Clin Cardiol 1990;13(6 Suppl 7):VII32-8.
16. Fujii M., Wada A., Ohnishi M., et al. Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure. J Cardiovasc Pharmacol 2004;44 Suppl 1:S346–9.
17. Мареев В.Ю. Основные достижения в области понимания, диагностики и лечения ХСН в 2003 году. Журнал Сердечная недостаточность 2004;(1):16–21.
18. Jorde U.P., Vittorio T.J., Dimayuga C.A., et al. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure. Am J Cardiol 2004;94(12):1501– 5.
19. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327(10):685–91.
20. McKelvie R.S., Rouleau J.L., White M. et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J 2003;24(19):1727–34.
21. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316(23):1429– 35.
22. Swedberg K., Kjekshus J., Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999;20:136–9.
23. Jong P., Yusuf S., Rousseau M.F. et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361(9372):1843–8.
24. Packer M., Poole-Wilson P.A., Armstrong P.W. et al. Comparative effects of low doses and high doses of the angiotensin converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure: ATLAS study group. Circulation 1999;100(23):2312–8.
25. Shindler D.M., Kostis J.B., Yusuf S. et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol 1996;77(11):1017–20.
26. Bourassa M.G., Gurn O., Bangdiwala S.I. et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993;22(4 suppl A):14A– 19A.
27. Willenheimer R., van Veldhuisen D.J., Silke B. et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112(16):2426–35.
28. Tu K., Mamdani M., Kopp A., Lee D. Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure. Am J Cardiol 2005;95(2):283–6.
